^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + lestaurtinib (CEP-701) (JAK2 inhibitor, FLT3 inhibitor, STAT5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Published date:
10/10/2023
Excerpt:
The drug combination affected all mut KRAS cell lines more extensively than single treatments, while no such pattern was seen in wt KRAS ones (Fig. 2A and Suppl. Fig. 2A)….Trametinib and Lestaurtinib combination is preferentially effective in mutant KRAS compared to wild type KRAS LUAD cells.
DOI:
https://doi.org/10.1038/s41467-023-41828-z
